...
首页> 外文期刊>Journal of Biotechnology >Antigen-mediated migration of murine pro-B Ba/F3 cells via an antibody/receptor chimera
【24h】

Antigen-mediated migration of murine pro-B Ba/F3 cells via an antibody/receptor chimera

机译:抗原介导的鼠pro-B Ba / F3细胞通过抗体/受体嵌合体的迁移

获取原文
获取原文并翻译 | 示例
           

摘要

Cell migration is one of the fundamental cellular responses governing development, homeostasis and disorders of the body. Therefore, artificial control of cell migration holds great promise for the treatment of many diseases. In this study, we developed an artificial cell migration system based on chimeric receptors that can respond to an artificial ligand that is quite different from natural chemoattractants. Chimeric receptors consisting of an anti-fluorescein single-chain Fv tethered to the extracellular D2 domain of erythropoietin receptor (EpoR) and the transmembrane/cytoplasmic domains of EpoR, gp130, interleukin-2 receptor, c-Kit, c-Fms, epidermal growth factor receptor (EGFR) or insulin receptor were expressed in the murine Ba/F3 pro-B cell line. Migration assays revealed that chimeric receptors containing the cytoplasmic domain of c-Kit, c-Fms or EGFR transduced migration signals in response to fluorescein-conjugated bovine serum albumin (BSA-FL). Furthermore, based on the cell migration in response to BSA-FL, we successfully selected genetically modified cells from mixtures of gene-transduced and untransduced cells. This study represents the first demonstration of cell migration in response to an artificial ligand that is quite different from natural chemoattractants, suggesting its potential application to immunotherapies and tissue engineering.
机译:细胞迁移是控制身体发育,体内稳态和疾病的基本细胞反应之一。因此,细胞迁移的人工控制对于治疗许多疾病具有广阔的前景。在这项研究中,我们开发了一种基于嵌合受体的人工细胞迁移系统,该系统可以响应与天然趋化剂完全不同的人工配体。嵌合受体,由抗荧光素单链Fv拴在促红细胞生成素受体(EpoR)的胞外D2结构域和EpoR的跨膜/胞质结构域,gp130,白介素2受体,c-Kit,c-Fms,表皮生长鼠Ba / F3 pro-B细胞系表达因子受体(EGFR)或胰岛素受体。迁移测定表明,包含c-Kit,c-Fms或EGFR胞质结构域的嵌合受体可响应荧光素偶联的牛血清白蛋白(BSA-FL)传导迁移信号。此外,基于响应BSA-FL的细胞迁移,我们成功地从基因转导和未转导的细胞混合物中选择了基因修饰的细胞。这项研究首次证明了细胞迁移对人工配体的反应,这种人工配体与天然趋化剂完全不同,表明其在免疫疗法和组织工程中的潜在应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号